admin – Page 3921 – Get News Story

Egerton Crescent Productions to Commence Principal Photography on “The Prince, the Sister, & the Serpent” Next Summer

Directed by Omar Parker, the new movie franchise features fantasy, action, and romance—exploring the myth of Cadmus, founder of Thebes, filming in the Mediterranean

NEW YORK – March 5, 2025 – Egerton Crescent Productions, founded by Charles Burt and Omar Parker, today announced it has scheduled principal photography on the feature film “The Prince, the Sister, and the Serpent,” based on the ancient Greek myth of Cadmus, the Phoenician founder of Thebes. Parker, a Lebanese American, will be directing, with Charles Burt, Amy Burt, and Abraham Mejorado producing. The fully funded project is being written and will begin filming in the summer of 2026. Principal photography will take place in a variety of locations across the Mediterranean.

“This is a remarkably old, incredibly important story,” said Parker. “It’s a fantastic opportunity to explore a myth that’s not as well-known and hasn’t been fleshed out in popular culture as much as other famous Greek heroes like Hercules or Perseus. The opportunity to bring this story to the public, something most have never seen on the big screen before, excites everyone at our company.”

The film tells the story of Cadmus, a prince of Phoenicia, who’s sister Europa is kidnapped by Zeus. He embarks on a quest he’ll never return from to find her. Along the way he’ll slay dragons, found Thebes, and find true love.

Since 2015, Egerton Crescent Productions has been making important movies, including official Cannes selections in the shorts category “Damiana” and “Eden.” Their films, “Ultraviolet” and “Mud,” were official selections at Sundance. Egerton’s “Luz: The Flower of Evil” was an official selection at the Sitges Film Festival in Spain, and is currently airing on Peacock in the United States.

The company founders, Charles Burt and Omar Parker, also have millions of Instagram followers and are Amazon bestsellers for their book “Inebriated Haikus.”

For more information visit https://www.egertoncrescentproductions.com

Media Contact
Company Name: Egerton Crescent Productions
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.egertoncrescentproductions.com

Nina Albanese Kotar’s Castor and Pollux Weaves a Haunting Tale of Music, Mythology, and Mystery

Castor and Pollux is a complex story spanning several generations and families that have in common two instruments, twin cellos, that hold a curse and dark family secrets. Timeless questions of mortality vs. immortality, love vs. hate, and creation vs. destruction are explored.

Northern Wisconsin – New Historical Mystery Novel Explores the Eerie Connections Between Twin Instruments, Forgotten Histories, and the Supernatural.

In her mesmerizing novel, Castor and Pollux, author Nina Albanese Kotar takes readers on a gripping journey where music, history, and the supernatural collide. This enthralling blend of historical fiction, mystery, and suspense is now available on Amazon (https://www.amazon.com/dp/B0DY521KFC).

A Mystery That Spans Centuries

At the heart of Castor and Pollux is Desca Reynolds, a gifted cellist and historian, whose life takes an unexpected turn when she stumbles upon a cryptic newspaper ad. Driven by an insatiable curiosity and an inexplicable connection to her antique cello, she embarks on a journey that unearths secrets buried deep within time.

As Desca delves into the enigmatic history of twin cellos and their former owners, she becomes entangled in a chilling mystery tied to a long-forgotten murder case in 1800s Whitechapel. Alongside her companions—Peter, a skilled violinist, and Rick, a stock analyst with unexpected ties to the past—she begins to uncover a series of eerie coincidences and supernatural phenomena that defy explanation.

What she discovers could change everything she thought she knew about music, ancestry, and fate.

A Story That Transcends Time

Castor and Pollux is not just a novel—it is an immersive experience that transports readers through London, Warsaw, Whitechapel, and beyond. Nina Albanese Kotar crafts a story that resonates on multiple levels, blending:

The Power of Music – An exploration of how sound, vibration, and the spirit of an instrument can transcend generations.

Historical & Mythological Depth – A masterful weaving of Greek mythology, real historical events, and lost legacies into a rich, multi-layered narrative.

A Haunting Mystery – A supernatural element that adds an eerie undertone, pulling readers deeper into the unknown.

A Strong Female Protagonist – Desca is not just unraveling a mystery—she is discovering herself, her past, and the unseen forces shaping her destiny.

About ‘Castor and Pollux’:

Castor and Pollux is a novel that brings together mythology, history, and mystery to create a captivating reading experience. Inspired by the legendary twin brothers of Greek mythology, the book explores themes of fate, identity, and the unbreakable bond between two souls. With a narrative that seamlessly blends historical intrigue and supernatural elements, the novel takes readers on a journey through time, unraveling secrets that bridge the past and present. Rich in atmospheric detail and compelling storytelling, Castor and Pollux appeals to fans of historical fiction, suspense, and mythology, offering a thought-provoking exploration of destiny and human connection.

What Makes ‘Castor and Pollux’ a Standout Read?

A Unique Blend of Music & Mystery – This novel dives into the world of classical instruments, their forgotten histories, and the energy they carry through time.
A Narrative That Moves Between Eras – The past and present intertwine seamlessly, keeping readers on the edge of their seats.
Atmospheric Settings – Each location—from the streets of London to the eerie corners of Whitechapel—is richly described, adding to the novel’s haunting allure.
Supernatural Undertones – A chilling and mysterious connection between twin cellos and their former owners lingers throughout the novel, adding depth, intrigue, and suspense.

Who Should Read ‘Castor and Pollux’?

This novel is perfect for:

Fans of Historical Fiction & Mystery – If you enjoy intricate, research-based narratives with historical depth, this book is for you.

Music Enthusiasts & Classical Fans – If the world of classical instruments, luthiers, and music’s emotional power fascinates you, Castor and Pollux delivers an unforgettable experience.

Supernatural & Gothic Fiction Readers – If you love eerie, unexplained connections tied to history, this novel’s haunting elements will keep you hooked.

Fans of Strong Female Leads – Desca’s intelligence, independence, and curiosity make her a protagonist worth following.

Mythology & Ancestry Enthusiasts – Readers interested in the Greek myth of Castor & Pollux, reincarnation, and forgotten legacies will find plenty to explore.

Meet the Author – Nina Albanese Kotar

Nina Albanese Kotar has always been a writer at heart, but Castor and Pollux was born from a series of life-changing events. The inspiration struck during a powerful moment—holding one cello while her daughter played another. The vibrations, the unspoken communication between musician and instrument, and the connection to something greater sparked the idea for this novel, which developed over several years.

Living in Northern Wisconsin, Nina enjoys the outdoors, music, travel, and storytelling. Her passion for history, classical music, and supernatural elements comes to life in Castor and Pollux, making it a truly one-of-a-kind reading experience.

Follow Nina Albanese Kotar on Social Media:

Facebook: https://www.facebook.com/profile.php?id=61573504461249

Instagram: https://www.instagram.com/p/DGO7py_RtG6/?igsh=b203ZjBxNnRleWN1

Website: www.thecastorandpollux.co

Key Message from ‘Castor and Pollux’

“The past has a voice, and through music, history, and connection, its echoes can still be heard. Sometimes, the answers to our deepest questions lie in the stories, artifacts, and melodies of those who came before us.”

Available Now – Get Your Copy!

Castor and Pollux is now available on Amazon: https://www.amazon.com/dp/B0DY521KFC

Media Contact
Contact Person: Nina Albanese-Kotar
Email: Send Email
Country: United States
Website: www.thecastorandpollux.co

Chemotherapy-induced Thrombocytopenia Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Amgen, Qilu Pharma, Jiangsu HengRui Medicine Co., Ltd., Sobi, Inc.

The Key Chemotherapy-induced Thrombocytopenia Companies in the market include – Amgen, Qilu Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Sobi, Inc., Beijing Northland Biotech, GlaxoSmithKline, Novartis, and others.

DelveInsight’s “Chemotherapy-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Chemotherapy-induced Thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chemotherapy-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy-induced Thrombocytopenia Market Forecast

Some of the key facts of the Chemotherapy-induced Thrombocytopenia Market Report:

The Chemotherapy-induced Thrombocytopenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Out of the 7MM, the United States had the most Chemotherapy-induced Thrombocytopenia incident cases. In 2020, there were an expected 111,445 Chemotherapy-induced Thrombocytopenia cases in the United States
Out of the EU-5, Germany has the most Chemotherapy-induced Thrombocytopenia incident cases. Germany had 35,025 Chemotherapy-induced Thrombocytopenia cases in 2020.
With 35,025 Chemotherapy-induced Thrombocytopenia incident cases, Germany ranked first out of the five major European nations. France and the UK came in second and third, with 26,333 and 25,975 cases, respectively. However, with 15,729 occurrences in 2020, Spain had the fewest cases overall.
There were 296,854 Chemotherapy-induced Thrombocytopenia incident cases in the 7MM overall in 2020. It is anticipated that the number of Chemotherapy-induced Thrombocytopenia cases in the 7MM will rise at a significant CAGR from 2019 to 2032, the duration of the study.
Key Chemotherapy-induced Thrombocytopenia Companies: Amgen, Qilu Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Sobi, Inc., Beijing Northland Biotech, GlaxoSmithKline, Novartis, and others
Key Chemotherapy-induced Thrombocytopenia Therapies: Nplate, QL0911, Romiplostim, Hetrombopag, Avatrombopag, NL201, SB497115, Eltrombopag olamine, Daunorubicin, and others
The Chemotherapy-induced Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy-induced Thrombocytopenia pipeline products will significantly revolutionize the Chemotherapy-induced Thrombocytopenia market dynamics.

Chemotherapy-induced Thrombocytopenia Overview

Thrombocytopenia is a condition characterized by a decrease in the number of platelets, which are tiny fragments of blood cells. Platelets, produced in the bone marrow along with other blood cell types, play a crucial role in clotting to stop bleeding when blood vessels are damaged. Given that platelets aid in clot formation, they are also referred to as thrombocytes.

https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-cit-market

Chemotherapy-induced Thrombocytopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chemotherapy-induced Thrombocytopenia Epidemiology Segmentation:

The Chemotherapy-induced Thrombocytopenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chemotherapy-induced Thrombocytopenia
Prevalent Cases of Chemotherapy-induced Thrombocytopenia by severity
Gender-specific Prevalence of Chemotherapy-induced Thrombocytopenia
Diagnosed Cases of Episodic and Chronic Chemotherapy-induced Thrombocytopenia

Download the report to understand which factors are driving Chemotherapy-induced Thrombocytopenia epidemiology trends @ Chemotherapy-induced Thrombocytopenia Epidemiology Forecast

Chemotherapy-induced Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-induced Thrombocytopenia market or expected to get launched during the study period. The analysis covers Chemotherapy-induced Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chemotherapy-induced Thrombocytopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy-induced Thrombocytopenia Therapies and Key Companies

Nplate: Amgen
QL0911: Qilu Pharmaceutical Co., Ltd.
Romiplostim: Amgen
Hetrombopag: Jiangsu HengRui Medicine Co., Ltd.
Avatrombopag: Sobi, Inc.
NL201: Beijing Northland Biotech
SB497115: GlaxoSmithKline
Eltrombopag olamine: GlaxoSmithKline
Daunorubicin: Novartis

Discover more about therapies set to grab major Chemotherapy-induced Thrombocytopenia market share @ Chemotherapy-induced Thrombocytopenia Treatment Market

Scope of the Chemotherapy-induced Thrombocytopenia Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chemotherapy-induced Thrombocytopenia Companies: Amgen, Qilu Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Sobi, Inc., Beijing Northland Biotech, GlaxoSmithKline, Novartis, and others
Key Chemotherapy-induced Thrombocytopenia Therapies: Nplate, QL0911, Romiplostim, Hetrombopag, Avatrombopag, NL201, SB497115, Eltrombopag olamine, Daunorubicin, and others
Chemotherapy-induced Thrombocytopenia Therapeutic Assessment: Chemotherapy-induced Thrombocytopenia current marketed and Chemotherapy-induced Thrombocytopenia emerging therapies
Chemotherapy-induced Thrombocytopenia Market Dynamics: Chemotherapy-induced Thrombocytopenia market drivers and Chemotherapy-induced Thrombocytopenia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chemotherapy-induced Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy-induced Thrombocytopenia Market Access and Reimbursement

To know more about Chemotherapy-induced Thrombocytopenia companies working in the treatment market, visit @ Chemotherapy-induced Thrombocytopenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chemotherapy-induced Thrombocytopenia Market Report Introduction

2. Executive Summary for Chemotherapy-induced Thrombocytopenia

3. SWOT analysis of Chemotherapy-induced Thrombocytopenia

4. Chemotherapy-induced Thrombocytopenia Patient Share (%) Overview at a Glance

5. Chemotherapy-induced Thrombocytopenia Market Overview at a Glance

6. Chemotherapy-induced Thrombocytopenia Disease Background and Overview

7. Chemotherapy-induced Thrombocytopenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chemotherapy-induced Thrombocytopenia

9. Chemotherapy-induced Thrombocytopenia Current Treatment and Medical Practices

10. Chemotherapy-induced Thrombocytopenia Unmet Needs

11. Chemotherapy-induced Thrombocytopenia Emerging Therapies

12. Chemotherapy-induced Thrombocytopenia Market Outlook

13. Country-Wise Chemotherapy-induced Thrombocytopenia Market Analysis (2019–2032)

14. Chemotherapy-induced Thrombocytopenia Market Access and Reimbursement of Therapies

15. Chemotherapy-induced Thrombocytopenia Market Drivers

16. Chemotherapy-induced Thrombocytopenia Market Barriers

17. Chemotherapy-induced Thrombocytopenia Appendix

18. Chemotherapy-induced Thrombocytopenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chemotherapy-induced Thrombocytopenia Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Amgen, Qilu Pharma, Jiangsu HengRui Medicine Co., Ltd., Sobi, Inc.

Corneal Edema Market in the US Projected for Significant Expansion from ~USD 489 Million in 2022 | DelveInsight

DelveInsight’s latest report on Corneal Edema forecasted significant growth in the US, driven by the emergence of new and effective treatments such as EO2002 ( Emmetrope Ophthalmics LLC), TTHX1114 (Trefoil Therapeutics), GLANATEC (D. Western Therapeutics Institute (DWTI)/Kowa Ltd.), STN1010904 (Santen Pharmaceutical) and others.

DelveInsight’s latest report, “Corneal Edema: Market Insights, Epidemiology, and Market Forecast-2034” combines robust epidemiological data with corneal edema market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market for corneal edema in the US is expected to grow positively from ~USD 489 million in 2022 over the coming years. This growth is attributed to improved diagnostic capabilities, a rising aging population contributing to an increase in corneal edema patient population, and the emergence of new and effective corneal edema treatments during the forecast period.

The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by total diagnosed prevalent cases of corneal edema, etiology-specific corneal edema diagnosed prevalent cases, and total treatable corneal edema cases in the US.

According to research conducted by DelveInsight’s analysts, the total diagnosed prevalence of corneal edema is approximately 1.18 million in 2023. The corneal edema diagnosed prevalent cases are further categorized based on mechanical, dystrophic, and inflammatory causes.

Discover evolving trends in Corneal Edema patient pool forecasts—Download sample report on Corneal Edema Epidemiology 2034 Analysis now!

The current treatment approach for corneal edema is dynamic and involves a tailored strategy based on the underlying cause and severity of the condition. Initial management often includes hypertonic saline solutions or hyperosmotic agents to reduce inflammation and draw excess fluid from the cornea. In cases where the corneal endothelium is severely compromised, surgical interventions or laser procedures, such as Selective Laser Trabeculoplasty (SLT), may be considered, particularly in cases associated with secondary glaucoma.

The treatment gap in corneal edema lies primarily in the absence of a universally effective and minimally invasive therapy that addresses the underlying causes and reverses the condition instead of focusing on managing symptoms or replacing damaged corneal tissue.

DelveInsight’s analysis reveals that a decent number of companies are launching clinical trials to address this unmet need in the corneal edema treatment landscape. The clinical development pipeline includes drugs such as EO2002 (Emmetrope Ophthalmics LLC), TTHX1114 (Trefoil Therapeutics), GLANATEC (D. Western Therapeutics Institute (DWTI)/Kowa Ltd.), AURN001 (Aurion Biotech) and STN1010904 (Santen Pharmaceutical), among others which are expected to enter the market during the forecast period and going to impact the trajectory of corneal edema market.

Unlock which corneal edema emerging drug is expected to capture the largest market share in 7MM by 2034 market, visit Corneal Edema Market Insights

In December 2024, AURN001, an allogeneic cell therapy by Aurion Biotech showed positive results in Phase 1/2 trials for the US market. EO2002, a nonsurgical cell therapy by Emmetrope Ophthalmics LLC demonstrated improvement in best-corrected visual acuity (BCVA) during a Phase 1 extension study as of November 2024. These developments highlight the momentum in this field.

Although corneal edema presents significant challenges, particularly due to the difficulty of early-stage detection, which can lead to ineffective management and increased severity, the emergence of more precise and sensitive diagnostic methods, along with novel therapies, is expected to expand treatment options and drive market growth.

Download the report to understand which factors are driving Corneal Edema market trends @ Corneal Edema Market Trends.

Table of Contents

1.	Key Insights
2.	Report Introduction
3.	Corneal Edema Market Overview at a Glance
3.1.	Market Share (%) Distribution by Therapies of Corneal Edema in 2020
3.2.	Market Share (%) Distribution by Therapies of Corneal Edema in 2034
4.	Epidemiology and Market Methodology of Corneal Edema
5.	Executive Summary of Corneal Edema
6.	Key Events
7.	Corneal Edema: Disease Background and Overview
7.1.	Introduction
7.2.	Etiology
7.3.	Pathophysiology
7.4.	Diagnosis
7.4.1.	Differential Diagnosis
7.4.2.	Diagnostic Algorithm
7.4.3.	Diagnostic Guidelines
7.4.3.1.	American Academy of Ophthalmology (AAO) 2018 Guideline for Corneal Edema and Opacification Preferred Practice Pattern
7.5.	Management
7.5.1.	Treatment Algorithm
7.5.2.	Treatment Guidelines
7.5.2.1.	AAO 2018 Guideline for Corneal Edema and Opacification Preferred Practice Pattern
8.	Corneal Edema Epidemiology and Patient Population
8.1.	Key Findings
8.2.	Assumptions and Rationale
8.2.1.	Etiology-specific Diagnosed Prevalent Cases of Corneal Edema
8.3.	The United States
8.3.1.	Total Diagnosed Prevalent Cases of Corneal Edema in the US
8.3.2.	Etiology-specific Diagnosed Prevalent Cases of Corneal Edema in the US
9.	Corneal Edema Patient Journey
10.	Corneal Edema Emerging Drugs
10.1.	Key Cross Competition
10.2.	EO2002: Emmetrope Ophthalmics LLC (“Emmecell”)
10.2.1.	Product Description
10.2.2.	Other Development Activities
10.2.3.	Clinical Development
10.2.4.	Clinical Trial Information
10.2.5.	Safety and Efficacy
10.2.6.	Product Profile
10.2.7.	Analysts’ Views
10.3.	TTHX1114: Trefoil Therapeutics
10.3.1.	Product Description
10.3.2.	Other Developmental Activities
10.3.3.	Clinical Development
10.3.4.	Clinical Trials Information
10.3.5.	Safety and Efficacy
10.3.6.	Product Profile
10.3.7.	Analyst Views
10.4.	GLANATEC (ripasudil/K-321): D. Western Therapeutics Institute (DWTI)/Kowa Ltd.
10.4.1.	Product Description
10.4.2.	Other Development Activities
10.4.3.	Clinical Development
10.4.4.	Clinical Trial Information
10.4.5.	Product Profile
10.4.6.	Analysts’ Views
10.5.	STN1010904 (sirolimus)/AE001: Santen Pharmaceutical/ Actual Eyes
10.5.1.	Product Description
10.5.2.	Other Developmental Activities
10.5.3.	Clinical Development
10.5.4.	Clinical Trials Information
10.5.5.	Product Profile
10.5.6.	Analyst Views
11.	Corneal Edema: Market Analysis
11.1.	Key Findings
11.2.	Corneal Edema Market Outlook
11.3.	Conjoint Analysis
11.4.	Key Market Forecast Assumptions
11.5.	Total Market Size of Corneal Edema in the US
11.6.	Market Size of Corneal Edema by Therapies in the US
12.	Key Opinion Leaders’ Views
13.	SWOT Analysis
14.	Corneal Edema Unmet Needs
15.	Market Access and Reimbursement
15.1.	The United States
15.1.1.	Center for Medicare and Medicaid Services (CMS)
16.	Appendix
16.1.	Bibliography
16.2.	Acronyms and Abbreviations
16.3.	Report Methodology
17.	DelveInsight Capabilities
18.	Disclaimer

Fuchs Endothelial Corneal Dystrophy Pipeline Insight provides comprehensive insights about the Fuchs Endothelial Corneal pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Fuchs Endothelial Corneal companies, including Trefoil Therapeutics, Kowa Pharmaceutical and Santen Pharmaceutical

Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Corneal Edema Market in the US Projected for Significant Expansion from ~USD 489 Million in 2022 | DelveInsight

Reus Research Rebrands as Cata-Kor: A New Era of Innovation in NAD+ Enhancement

Pioneering the Future of NAD+ Supplementation with Advanced LipoNAD+ Technology and a Renewed Commitment to Scientific Excellence.

Miami, FL – Mar 5, 2025 – Reus Research, a leader in NAD+ supplementation and longevity science, is officially rebranding as Cata-Kor, marking a bold step forward in its commitment to innovation, scientific integrity, and superior health solutions.

“We are evolving beyond our original identity to reflect our advancements in longevity science while staying true to our mission of supporting elevated NAD+ levels for better health and vitality,” said Uladzimir Seuruk, Founder & CEO of Cata-Kor. “With this transition, we are introducing a groundbreaking new formula, enhanced technology, and a stronger commitment to quality.”

As part of the rebrand, Cata-Kor is unveiling a revamped formula that eliminates Nicotinamide Riboside (NR) and Quercetin, replacing them with patented LipoNAD+ and Resveratrol. The exclusive LipoNAD+ technology features a lipid-coated delivery system that bypasses stomach breakdown and is more readily absorbed in the intestines, optimizing cellular energy production and repair. Additionally, Cata-Kor is reinforcing its commitment to quality and transparency by shifting to 100% U.S.-based production, ensuring every supplement meets the highest safety and manufacturing standards.

Despite these changes, Cata-Kor remains dedicated to its core mission. The supplement continues to elevate NAD+ levels, supporting energy, longevity, and cellular health. The formula remains scientifically backed, with each serving delivering 500 mg of active ingredients for optimal results. Cata-Kor products will continue to be available on TikTok Shop and Amazon, ensuring accessibility for health-conscious consumers.

Leading this transformation is Seuruk, the pioneering researcher behind the brand. While the name has evolved, Cata-Kor’s signature packaging and recognizable product color remain unchanged, maintaining continuity and trust with its customers.

This rebranding marks a pivotal moment in longevity science, reinforcing Cata-Kor’s commitment to cutting-edge innovation and consumer trust.

For more information, visit https://catakor.com.

Media Contact
Company Name: Otter PR
Contact Person: Mark Hashem
Email: Send Email
Phone: 7274339069
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Reus Research Rebrands as Cata-Kor: A New Era of Innovation in NAD+ Enhancement

2025’s Drone Innovators: The Companies Shaping the Future of Flight

Drones have come a long way from being fancy gadgets for hobbyists. Today, they’re revolutionizing industries like agriculture, logistics, defense, and emergency response. The global drone market is already a $30 billion powerhouse, and it’s growing at a solid 10.6% annually. With AI, advanced automation, and innovative models like Drone as a Service (DaaS), the potential is massive.

A handful of companies are stepping up with cutting-edge tech, big contracts, and bold visions for the future. These players aren’t just keeping pace with the industry—they’re shaping its trajectory. Let’s take a closer look at some of the key innovators driving this high-flying sector.

ZenaTech (Nasdaq: ZENA) is a technology company specializing in AI-powered drones and innovative solutions for defense, agriculture, logistics, and infrastructure. With a strong focus on military applications and a unique Drone as a Service (DaaS) model, ZenaTech is carving out a significant role in the rapidly growing drone industry.

The company’s drones are already being tested by the U.S. Air Force and Navy for critical tasks like transporting medical supplies in the field. ZenaTech is also working toward Blue UAS certification, which would allow the U.S. Department of Defense to purchase their drones directly. This is a major opportunity, as the global military drone market is expected to grow from $14 billion in 2023 to $47 billion by 2032.

ZenaTech’s DaaS model is another key differentiator. Instead of selling drones outright, the company offers them as a service, making drone technology more accessible to businesses and governments. For example, ZenaTech is using drones to improve border security in Florida, where they can monitor coastlines and assist in search-and-rescue operations. This approach not only opens up new revenue streams but also makes drones more affordable for a wider range of customers.

The company is also investing in advanced technology, including AI for improved drone performance and DroneNet, a proprietary communication system that allows drones to operate in areas without internet or cellular service. This is especially important for military missions where reliable communication is critical. ZenaTech is even exploring the use of quantum computing to enhance applications like weather forecasting and traffic management, which could give them a competitive edge in the future.

With manufacturing facilities in the UAE and Arizona, ZenaTech is well-positioned to scale up production. Their latest drone, the ZenaDrone 1000, is designed for heavy lifting and long flight times, making it ideal for both military and commercial use. The company plans to produce at least ten drones per month starting in 2025, demonstrating their commitment to meeting growing demand.

ZenaTech’s (Nasdaq: ZENA) focus on defense contracts, innovative business models, and advanced technology makes it a standout in the drone sector. If the company can execute its plans—especially securing military certifications—it could see growth in the coming years. For investors looking to capitalize on the drone industry, ZENA is a stock worth watching.

AeroVironment, Inc. (NASDAQ: AVAV) is a global leader in intelligent, multi-domain robotic systems, serving defense, government, and commercial markets. With a strong focus on cutting-edge drone technology and autonomous systems, the company has cemented its position as a key player in the rapidly growing drone sector.

In February 2025, AeroVironment secured a $288 million delivery order as part of a $990 million contract with the U.S. Army for its Switchblade loitering munition systems. This contract highlights the company’s critical role in providing advanced, precision-strike capabilities to the military. The Switchblade system, known for its extended range and multi-domain operations, is a testament to AeroVironment’s ability to deliver mission-critical solutions.

The company also announced the establishment of FreedomWerx, a state-of-the-art manufacturing facility in Salt Lake City, Utah. This expansion is part of AeroVironment’s distributed production strategy, designed to enhance supply chain resilience and meet growing demand for its autonomous systems. The facility is expected to create over 500 high-paying jobs and further solidify the company’s manufacturing capabilities.

AeroVironment continues to push the boundaries of drone technology with the launch of the JUMP 20-X, a next-generation Group 3 uncrewed aircraft system (UAS) designed for maritime operations. Unveiled at the 2025 International Defence Exhibition & Conference (IDEX), the JUMP 20-X offers unmatched versatility, endurance, and precision. With a 13-hour flight endurance, modular payload capacity, and AI-powered autonomy, the system is poised to revolutionize maritime and expeditionary missions.

AeroVironment’s growth is driven by its strong defense contracts, technological leadership, and strategic investments. As demand for autonomous systems continues to rise, the company is well-positioned to deliver sustained growth and shareholder value, making it a compelling choice for investors in the drone sector.

EHang (Nasdaq: EH) is a global leader in urban air mobility (UAM), pioneering autonomous, eco-friendly aerial vehicles that are reshaping transportation. Its flagship product, the EH216-S, is the world’s first fully certified pilotless eVTOL aircraft, approved by the Civil Aviation Administration of China (CAAC). This certification underscores EHang’s technological leadership and positions it at the forefront of the UAM industry.

In 2024, EHang delivered record-breaking results, with fourth-quarter revenues reaching RMB162 million, a 20% increase over guidance and a 187% year-over-year jump. This growth was driven by strong demand for the EH216-S, which has become a cornerstone of the company’s strategy. The aircraft made its debut flight in downtown Shanghai in January 2025, marking a major milestone toward commercial air taxi operations in one of the world’s largest cities. The flight, conducted at Longhua Airport, showcased the EH216-S’s capabilities in urban environments and set the stage for future commercial routes in the Yangtze River Delta region.

EHang is also building the infrastructure to support its vision. The company launched the Luohu UAM Exhibition Center in Shenzhen, featuring the world’s first fully automated vertiport for the EH216-S. This facility, with its vertical lift platform and integrated hangar, represents a leap forward in eVTOL operations, reducing costs and optimizing space usage. Strategic partnerships with JAC Motors and Guoxian Holdings further solidify EHang’s position in the low-altitude economy. The collaboration aims to establish a state-of-the-art eVTOL manufacturing base in Hefei, combining EHang’s cutting-edge technology with JAC Motors’ automotive expertise to scale production and meet growing demand.

With its first-mover advantage, regulatory milestones, and expanding infrastructure, EHang is well-positioned to capitalize on the booming low-altitude economy, projected to exceed RMB50 billion in Shanghai alone by 2027. For investors, EHang represents a high-growth opportunity in a transformative industry.

AgEagle Aerial Systems Inc. (NYSEAMERICAN: UAVS) is a growing force in the drone sector, specializing in full-stack unmanned aerial systems (UAS), sensors, and software solutions for commercial and government applications.

Originally focused on agriculture, AgEagle has expanded into energy, construction, and defense verticals, delivering innovative drone technology that addresses critical industry needs.

In 2025, the company achieved significant milestones, including a successful demonstration of its eBee VISION ISR platform for the U.S. Department of Defense, showcasing its capabilities in intelligence, surveillance, and reconnaissance. AgEagle also secured a $3.4 million order from the French Army—its largest single order to date—and announced that its eBee drones are the most used fixed-wing drones by U.S. commercial operators, based on FAA registration data.

The company further strengthened its global presence at the XPONENTIAL Europe trade show, where its products were featured by major partners like Rheinmetall and Dronivo. Recently, AgEagle completed a milestone order of 60 RedEdge-P Multispectral Sensors, its largest sensor sale ever, highlighting its operational efficiency and market demand.

With a focus on innovation, strategic partnerships, and expanding global footprint, AgEagle is well-positioned to capitalize on the growing UAS market, making it a compelling opportunity for investors.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 2025’s Drone Innovators: The Companies Shaping the Future of Flight

Citadel Contracting Expands Roofing Services in Raleigh Area

Citadel Contracting, a prominent roofing contractor in Raleigh, is excited to announce the expansion of its roofing services for residential and commercial properties. With a team of skilled professionals and years of experience, Citadel Contracting has earned a reputation for delivering high-quality roofing solutions throughout the region.

The company’s services include expert Roof Repair Raleigh, Roof Replacement Raleigh, and New Roof Installation Raleigh. Whether addressing minor leaks or handling extensive damage, Citadel Contracting offers reliable repairs to restore roofs to their optimal condition. For properties in need of a complete overhaul, the company specializes in roof replacements using the best materials and techniques available. Additionally, their new roof installations provide clients with a range of roofing options to suit different preferences and budgets.

Citadel Contracting ensures that every project is completed with the utmost attention to detail and quality craftsmanship. The company’s experienced team works diligently to provide cost-effective solutions that meet each client’s specific needs. Whether residential or commercial, Citadel Contracting’s services are designed to provide lasting protection against the elements, improve property value, and enhance curb appeal.

The company’s reputation for reliable and efficient service has made it a trusted choice for homeowners and business owners in Raleigh. Citadel Contracting is fully licensed, insured, and bonded, offering peace of mind to all clients.

Media Contact
Company Name: Citadel Contracting
Contact Person: Nicholas Capps
Email: Send Email
Phone: (252) 651-4719
City: Raleigh
State: North Carolina 27613
Country: United States
Website: https://citadel-contracting.com/

Raffiti Media Launches the Business Viral System: Transforming Viral Views Into Business Growth

Every business owner dreams of going viral, but few know how to turn viral success into real, sustainable revenue. Raffiti Media, led by viral video expert Scott Simson, is changing that with the launch of the Business Viral System—a step-by-step program designed to help business owners, entrepreneurs, and content creators convert viral video views into leads and revenue.

Simson has successfully leveraged viral content for business growth, garnering over 200 million views. The Business Viral System is built on proven frameworks and strategies, offering a structured approach to scaling businesses through strategic video content rather than relying on outdated trial-and-error methods.

The Problem: Why Going Viral Isn’t Enough

Many business owners struggle with content marketing. They spend countless hours brainstorming, filming, and posting videos, only to see little engagement and no impact on their bottom line. Chasing trends and hoping for success is not a strategy—it’s a gamble.

“I used to spend $20,000 a month on Facebook ads just to generate leads,” says Quazi Johir, a Business Viral System student. “Now, I’m getting paid $15,000 from YouTube alone. The shift from ad dependency to organic, viral-driven growth has been a game-changer for my business.”

The Solution: A Proven System for Business Virality

The Business Viral System is more than just a guide to getting views—it’s a comprehensive framework designed to turn viral content into an automated lead-generation machine.

The system teaches business owners how to:

Create high-impact content that attracts, engages, and converts viewers into paying customers.
Leverage social media platforms like YouTube, Instagram, and LinkedIn to maximize reach and revenue.
Use structured processes, including the Viral Video Framework and Content Ideation Guide, to simplify video creation.
Optimize short-form content on TikTok, Instagram Reels, and YouTube Shorts for consistent lead generation.
Follow up with viral audiences to extend content impact and drive more sales.

What’s Inside the Business Viral System?

For a limited-time launch price of just $29 (originally $237), users will receive instant digital access to the full Business Viral System, including:

The Business Viral Video Framework: A step-by-step blueprint for crafting high-performing videos.
The Viral Content Ideation Guide: A process for identifying high-converting content ideas.
Short-Form Content Optimization Guide: Strategies to transform views into leads on TikTok, Instagram Reels, and YouTube Shorts.
Follow-Up Strategies for Viral Content: Learn how to keep momentum going even after a video goes viral.
The Quick-Start Viral Checklist: A one-page, actionable roadmap to executing the viral content strategy efficiently.

Results-Driven, Backed by Experience

Unlike many social media growth courses that focus solely on getting more views, the Business Viral System is built on real-world success. Simson’s approach is backed by data-driven strategies that have helped businesses generate millions in revenue—all without relying on paid ads.

Who Is This System For?

The Business Viral System is ideal for:

Business owners looking to scale using social media.
Content creators who want to build an audience and monetize their views.
Entrepreneurs and coaches seeking a structured approach to social media marketing.
Brands that want a sustainable way to generate leads through organic content.

The Future of Business Growth Is Viral

In 2025, content is currency—and those who know how to create viral, high-converting videos will dominate their industries. The Business Viral System isn’t just about trends—it’s about turning social media into a business growth engine.

Interested entrepreneurs can learn more and get instant access to the Business Viral System by visiting https://getbusinesswithvideo.com/businessviralsystem.

Media Contact
Company Name: Raffiti Media
Contact Person: Orlena Johnson
Email: Send Email
City: Dallas
State: Texas
Country: United States
Website: www.raffitimedia.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Raffiti Media Launches the Business Viral System: Transforming Viral Views Into Business Growth

Father’s House Restoration Ministries Launches a Community Land Trust (CLT)

Father’s House Restoration Ministries, in Partnership with Asset Manager Conscious Markets, Launches Community Land Trust to Transform Oroville.

Oroville, California – On January 29th, 2025, Father’s House Restoration Ministries (FHRM), advised by Conscious Markets Group company CMG Revival Partners, announced the launch of the Father’s House Oroville Community Land Trust (FHOCLT), in a local townhall. The FHOCLT is a nonprofit, spirit-filled initiative dedicated to providing low to lower-income residents with affordable housing, homeownership opportunities, and training, and fostering sustainable community development in Oroville, California.

Goals of the Community Land Trust

The Community Land Trust aims to revitalize the community by collaborating with residents, investors, institutions, and real estate developers to increase affordable homeownership opportunities. By retaining ownership of the land and regulating rents, the FHOCLT ensures long-term housing stability for low-income residents. Additionally, the trust offers lease-to-own options, empowering individuals to transition from renting to owning their homes.

Members of the Community Land Trust benefit from access to financial, business, and wellness support programs. Universal membership privileges include voting on board requested decisions, participation in skills and vocational training, and priority notifications for housing opportunities and innovative programs. Resident members enjoy further advantages, such as exclusive access to affordable rental and homeownership options.

Funding for the Community Land Trust is sourced from public and private grants, donations, and partnerships with developers and property owners. These resources support property acquisition, development, and essential programs like credit and homeowner training. In collaboration with CMG Revival Partners, FHRM is also set to launch the Father’s House Restoration Opportunity Fund in 2025, offering investors access to federal Opportunity Zone capital gains tax benefits.

“Building upon over three decades of community service, Father’s House Restoration Ministries (FHRM) has significantly impacted Oroville through various initiatives, including low-income housing, food assistance programs, and support for individuals recovering from addiction and trauma.

“The establishment of the Father’s House Oroville Community Land Trust marks a pivotal step in FHRM’s ongoing commitment to fostering generational stability and prosperity within the community. We are excited to see what God plans for City of Oroville.” – Ifeanyi Jemie, CEO of CMG

For more information about the Father’s House Oroville Community Land Trust and how to participate, please visit https://RestoreOroville.org/CLT.

About Father’s House Restoration Ministries

Father’s House Restoration Ministries is a registered 501(c)(3) nonprofit organization dedicated to transforming communities through faith-driven programs, affordable housing, and sustainable development initiatives. With hearts for serving low-income individuals and families, FHRM strives to create lasting positive change in Oroville and beyond. Over the last 30 years, the team has been responsible for clearing over 150 tons of trash from the southside of Oroville and currently manages 100 beds of housing. This is a separate entity from The Father’s House Church with some shared leadership.

About Conscious Markets Group

Conscious Markets Group, and its impact real estate investment management arm CMG Revival Partners LLC is an impact investment and community development advisory firm, with a management team having over 90 years of experience in financial services, community development advisory, non-profit and faith-driven advisory and civil engineering.

For membership or general inquiries, contact us at email: Info@RestoreOroville.org. For investor inquiries, contact us at Team@ConsciousMarketsGroup.com.

Media Contact
Company Name: Father’s House Oroville Community Land Trust
Contact Person: Public Relations
Email: Send Email
Phone: +1 (424) 703-5495
City: Oroville
State: California
Country: United States
Website: https://RestoreOroville.org/CLT

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Father’s House Restoration Ministries Launches a Community Land Trust (CLT)

Schneider Electric Eyes Expansion With Rs 3,200-crore India Investment

Schneider Electric, a global leader in energy management and automation, is ramping up its operations in India with a Rs 3,200-crore investment. The company plans to set up new manufacturing plants in Kolkata and Hyderabad while expanding capacity at its existing facilities.

Speaking to FE, Manish Pant, executive vice-president (International Operations), said that the company is optimistic about a sea of opportunities in India and has firm plans for continued investments in the country. “We have already announced about Rs 3,200 crores of investment and we continue to expand our factories. In the recent past, we have inaugurated factories in Bangalore, we have made a new factory in Hyderabad, and we have announced the expansion in our vacuum factories, where we make medium voltage circuit breakers in Kolkata,” he said.

Highlighting the growth areas, Pant said India, the US, and West Asia are the three big growth markets for the company. “The way the economy is growing, the way the energy transition is growing in India, we are very strongly committed and have a very strong presence here. We need to continue to invest here to match the growth,” he added.

“We are making sure that we bring the world-class industrial facilities and at the same time, there is an expansion of our capacities to meet the demand in India, but that expansion demand has to come with new innovations that we are also doing in India,” he said.

With its Lauritz Knudsen brand, Schneider Electric aims to develop localised solutions across sectors, from agriculture to infrastructure. Meanwhile, through Luminous Power Technologies, the company focuses on serving the residential market.

Speaking on its financial performance, Pant noted that the company’s margins at the global level are healthy with its EBITDA margin at 18.6% and Schneider hopes to maintain healthy growth. India, the US, and West Asia are the three areas where the company sees the largest growth coming to 2027.

Pant highlighted Schneider Electric’s robust financial performance, stating that the company maintains strong global margins, with an Ebitda margin of 18.6%. He identified India, the US and West Asia as the primary growth engines, driven by increasing demand for energy solutions, infrastructure expansion, and digital transformation. The company remains committed to sustained investments in these regions to capitalise on emerging opportunities through 2027.

“We can bring more digitization, and that is our focus because it significantly helps customers optimize power usage within their homes,” Pant said.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Eyes Expansion With Rs 3,200-crore India Investment